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http://www.cardiothoracicsurgery.org/content/8/1/183RESEARCH ARTICLE Open AccessAssessment of a novel, capsid-modified adenovirus
with an improved vascular gene transfer profile
Katie M White1, Raul Alba1,2, Alan L Parker1,3, Audrey F Wright1, Angela C Bradshaw1, Christian Delles1,
Robert A McDonald1 and Andrew H Baker1*Abstract
Background: Cardiovascular disorders, including coronary artery bypass graft failure and in-stent restenosis remain
significant opportunities for the advancement of novel therapeutics that target neointimal hyperplasia, a
characteristic of both pathologies. Gene therapy may provide a successful approach to improve the clinical
outcome of these conditions, but would benefit from the development of more efficient vectors for vascular gene
delivery. The aim of this study was to assess whether a novel genetically engineered Adenovirus could be utilised
to produce enhanced levels of vascular gene expression.
Methods: Vascular transduction capacity was assessed in primary human saphenous vein smooth muscle and
endothelial cells using vectors expressing the LacZ reporter gene. The therapeutic capacity of the vectors was
compared by measuring smooth muscle cell metabolic activity and migration following infection with vectors that
over-express the candidate therapeutic gene tissue inhibitor of matrix metalloproteinase-3 (TIMP-3).
Results: Compared to Adenovirus serotype 5 (Ad5), the novel vector Ad5T*F35++ demonstrated improved binding
and transduction of human vascular cells. Ad5T*F35++ mediated expression of TIMP-3 reduced smooth muscle cell
metabolic activity and migration in vitro. We also demonstrated that in human serum samples pre-existing
neutralising antibodies to Ad5T*F35++ were less prevalent than Ad5 neutralising antibodies.
Conclusions: We have developed a novel vector with improved vascular transduction and improved resistance to
human serum neutralisation. This may provide a novel vector platform for human vascular gene transfer.
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Pre-clinical studies indicate that gene delivery to the vas-
culature could potentially be utilised to treat a range of
cardiovascular diseases such as vein graft failure [1], in-
stent restenosis [2] and peripheral vascular disease [3].
Although clinical trials have generally identified no ser-
ious side effects, phase II and III randomised control tri-
als have failed to achieve the promising efficacy seen in
animal models and earlier trials [4-7], suggesting that
further optimisation of the treatments is required. One
of the more successful phase II clinical trials utilised
intracoronary injection of an Adeno-associated Virus-1
vector to over-express the sarcoplasmic reticulum Ca2+-* Correspondence: Andrew.H.Baker@glasgow.ac.uk
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reproduction in any medium, provided the orATPase gene (SERCA2a) in patients with advanced heart
failure [8]. This treatment significantly improved several
cardiovascular parameters [8] and demonstrates the future
potential of gene therapy treatments targeting the cardio-
vascular system. Critical to realising this potential is the
development of more efficient gene delivery systems to gen-
erate sufficient levels of therapeutic transgene expression,
specifically at the target site without causing any adverse
effects.
In general, the commonly used viral vector Ad5 poorly
transduces the vasculature, although, when high doses of
virus are applied to intact blood vessels this vector can
produce high levels of transgene expression in endothe-
lial cells (EC) and, depending on the level of damage to
the endothelial layer, lower levels in smooth muscle cells
(SMC) [9-11]. Clearly, clinical indications define the route
of vector delivery and this often requires short exposuretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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delivery achievable. Analysis of the vascular expression of
the coxsackie and adenovirus receptor (CAR), a primary
Ad5 receptor, has shown that EC and SMC from a number
of different vascular beds express a very low level of CAR
[12-14], and analysis of intact human blood vessels could
not detect CAR expression [15]. Havenga et al. have previ-
ously demonstrated that Ad5 vectors pseudotyped with the
fiber from several subgroup B viruses show enhanced trans-
duction of human vascular cells compared to Ad5 [16] and
the Ad subgroup B receptor CD46 has been shown to be
relatively highly expressed by vascular cells [12]. Therefore
to maximise uptake into the vessel we have focused on de-
veloping a vector which utilises CD46 and not CAR as the
principal receptor for binding to the cell surface.
An additional clinical consideration associated with the
use of Ad5 vectors is that between 30 and 93% of the
population (depending on the location of population) have
pre-existing Ad5 neutralising antibodies [17,18], which can
significantly limit the efficacy of transgene expression [19].
It has been demonstrated that modifying either the hexon
protein [20] or pseudotyping Ad5 with the fiber of other
Ad serotypes [21] can reduce the propensity of serum neu-
tralisation of the virus.
Bio-distribution of the virus is also an important con-
sideration when assessing potential off-target effects of
gene therapy. Studies have shown that following catheter
mediated delivery of an Ad5 vector to rabbit aortas, sub-
stantial transgene expression was detected in non-target
tissues including hepatocytes, circulating monocytes and
the testis [22], indicating that vector leakage from the
target vascular tissue may remain a potential safety issue
even when direct application of the vector to the vascu-
lature is used. Hepatocyte uptake of Ad5 is mediated by
the Ad5 hexon protein binding to circulating coagula-
tion factor X (FX) [23,24], which then acts as a bridge to
heparan sulphate proteoglycans [25]. Mutation of the FX
binding site in the hexon protein has been shown to sig-
nificantly reduce liver uptake [26-28]. Thus ablation of
FX binding may offer the additional advantage of limit-
ing any potential off-target effects.
In order to maximise gene delivery to vascular cells,
whilst minimising the dose of virus required, we aimed to
develop a modified Ad vector with the required attributes
to produce enhanced vascular transduction. We have com-
bined selective hexon amino acids mutations to ablate FX
binding and simultaneous fiber pseudotyping in order to
engineer a vector with improved gene delivery to vascular
cells.
Methods
Ethics approval
Ethical approval (Ref 06/S0703/110) was obtained for
the use of human saphenous vein and serum samplesfrom patients undergoing coronary artery bypass grafting
(CABG).
Generation of Ad vectors
All viruses were based on the AdEasy, E1/E3-deleted
Ad5 vector (Stratagene, Leicester, UK). Ad5 LacZ vectors
were generated as previously described [26]. TIMP-3 ex-
pressing viruses were produced by cloning the TIMP-3
transgene into pShuttle-CMV plasmid (Stratagene). Hom-
ologous recombination between pShuttle-CMV TIMP-3
and the capsid encoding plasmids pAdEasy, pAd5CMV-
HVR5*7*E451Q (Ad5T*) and pAd5CMV-HVR5*7*E451
Q/F35++ (Ad5T*F35++) [26] was performed in BJ5183
electro-competent cells. Viruses were generated by trans-
fection of HEK293 cells. All viruses were purified by CsCl
gradient centrifugation and titred by end-point dilution to
quantify plaque forming units (pfu) [29]. Particle titres were
calculated from protein concentration using the Micro-
Bicinchoninic Acid Protein Assay kit (Thermo Scientific,
Cramlington, UK) and the formula 1 μg protein = 4x109 vi-
rus particles [29] and confirmed by NanoSight measure-
ment (NanoSight, Wiltshire, UK).
Cell culture
All cells were cultured in a humidified atmosphere with
5% CO2 at 37°C. HSVSMC were isolated from medial
explants of human saphenous vein samples received
from patients undergoing CABG surgery. Cells were cul-
tured in Smooth Muscle Cell Growth Medium 2 (Pro-
moCell, Heidelberg, Germany) supplemented with 15%
foetal bovine serum (PAA Laboratories, Somerset, UK),
2 mM L-Glutamine (Invitrogen, Paisley, UK) and 1%
penicillin-streptomycin (Invitrogen). HSVEC were obtained
by enzymatic collagenase digestion of human saphenous
veins and were maintained in Large Vessel Endothelial
Cell Basal Medium (TCS CellWorks, Buckinhgham, UK)
supplemented with 20% foetal bovine serum (PAA Labora-
tories), 2 mM L-Glutamine (Invitrogen) and 1% penicillin-
streptomycin (Invitrogen, Paisley, UK). A549 cells (human
lung carcinoma, ATCC CCL-185) were maintained in
RPMI160 supplemented with 10% foetal bovine serum
(PAA Laboratories), 2 mM L-Glutamine (Invitrogen) and
1% penicillin-streptomycin (Invitrogen).
Analysis of virus:cell binding
Cells were seeded at 2x105 cells/well in 24 well plates.
The following day cells were cooled to 4°C for 30 mi-
nutes, washed in PBS then incubated for 1 hour at 4°C
in serum free media containing 5000 vp/cell of virus. DNA
was extracted using the QIAmp DNA Mini Kit (Qiagen,
West Sussex, UK) according to the manufacturer’s proto-
col. DNA was quantified using ND-1000 Nanodrop spec-
trophotometer. Viral genomes were quantified in 100 ng
DNA by quantitative SyBR green real time PCR (Applied
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primers [30].
In vitro transduction of vascular cells
Cells were seeded at 2x104 cells/well in 96 well plates.
The following day cells were infected with 5000 vp/cell
in serum free media. Cells were incubated for 3 hours
at 37°C, washed in PBS then incubated for a further
48 hours in complete media.
For antibody blocking experiments cells were pre-
incubated for 1 hour at 4°C in serum free media containing
5 μg/ml mouse anti human CD46 antibody MEM-258
(AbD Serotec, Oxford, UK) or mouse IgG1 isotype control
(Dako, Glostrup, Denmark). Infections and transgene quan-
tification were then performed as described above.
β-galactosidase detection
For visualisation of β-Galactosidase expression, cells were
washed in PBS, fixed in 4% PFA and stained in X-gal. β-
Galactosidase activity was quantified using Tropix Galacton
Plus (Applied Biosystems) according to the manufacturer’s
instructions. Protein concentrations were measured by
BCA assay (ThermoScientific, Leicestershire, UK) accord-
ing to the manufacturer’s instructions. Absorbances were
measured using a Wallac VICTOR2 (PerkinElmer Life and
Analytical Sciences, Boston, USA) and values were ex-
pressed as relative light units/mg protein.
Serum neutralisation assay
Human serum samples (102 patients) were obtained from
a Scottish cohort of patients undergoing CABG surgery.
Based on a previously established protocols [21,31] A549
cells were infected with 10000 vp/cell in the presence or ab-
sence of 2.5% serum. β-Gal activity was measured 48 hours
post infection and normalised to total protein levels asFigure 1 In vitro profiling of virus binding to A. HSVSMC and B. HSVE
genomes were detected by quantitative PCR (* = p < 0.05 vs Ad5, *** = p <described above. Serum samples which caused >90% inhib-
ition of transduction were considered to be neutralising.
Detection of TIMP-3 expression
Infections were performed as described above. 36 hours
post infection 1:1000 dilution of Monensin (Biolegend,
London, UK) was added to the culture medium and in-
cubated for a further 12 hours.
For immunocytochemistry, cells were permeabilised in
PBS-Tween, blocked in goat serum (Dako), then incubated
with Rabbit anti-human TIMP-3 antibody (Millipore) or
Rabbit IgG control. Goat anti-rabbit Alexa 546 (Invitrogen)
was used for detection. Slides were mounted using Prolong
Gold with DAPI (Invitrogen) and imaged using Zeiss con-
focal imaging system LSM500.
For Western blotting, denatured cell samples were sepa-
rated on a 12% SDS polyacrylamide gel. TIMP-3 expression
was detected using Rabbit anti-human TIMP3 antibody
(Millipore), and swine anti-rabbit-HRP antibody (Dako).
Blots were stripped and re-probed using mouse anti-
human β-actin monoclonal antibody (AbCam) and rabbit
anti-mouse-HRP (Dako).
Scratch assay
Cells were infected as described above. A previously de-
scribed scratch assay was then used [32]. Briefly, 48 hours
post infection, a 200 μl pipette tip was used to produce
three evenly sized vertical scratches per well, cells were
washed with PBS and placed in fresh media. Images were
captured at 0, 12 and 19 hours post-scratch.
Cell metabolic activity
Cells were infected as described above. Metabolic activity
was analysed 48 hours post infection using the CellTiter96®
AQueous One Solution Cell Proliferation Assay (Promega).C. 5000 vp/cell were allowed to bind cells for 1 hour at 4°C. Ad
0.001 vs Ad5).
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Results presented are representative data from a mini-
mum of three separate experiments with three experi-
mental replicates per group. All results are shown as
mean+/−SEM. Values were compared using One-way-
ANOVA with Tukey’s Multiple Comparison Test. p < 0.05
was considered significant.
Results and discussion
In vitro binding and transduction profiles of a CD46
binding Ad vector in human vascular cells
Surface plasmon resonance has previously demonstrated
that mutations in the hexon protein of the virus Ad5T*
prevent binding to FX, and following systemic delivery
in mice, this ablation of FX binding causes a significantFigure 2 In vitro virus transduction. β-Gal activity and representative imag
vp/cell for 3 hours at 37°C. β-Gal activity was normalised to total protein level
activity normalised to total protein in (C) HSVSMC and (D) HSVEC infected wi
antibody MEM258 or an isotype matched control. (* = p < 0.05 relative to isotreduction in liver tropism [26]. Pseudotyping this vector
with the Ad35++ fiber (Ad5T*F35++) enables cellular
binding and transduction to occur through an interac-
tion with CD46 [26]. To exploit the relatively high level of
CD46 expression on human vascular cells [12] we inves-
tigated the efficacy of Ad5T*F35++ for gene delivery to
these cells.
Initially we performed in vitro cell binding and transduc-
tion experiments with β-galactosidase expressing vectors
to compare Ad5, Ad5T* and Ad5T*F35++. Ad5T*F35++
showed significantly higher levels of binding to human sa-
phenous vein smooth muscle cells (HSVSMC) and human
saphenous vein endothelial cells (HSVEC) compared to
Ad5 (Figure 1). This correlated with increased cellular
transduction as Ad5T*F35++ produced significantly higheres of X-gal stained cells in A. HSVSMC and B. HSVEC infected with 5000
s (* = p < 0.05 compared to Ad5, *** = p < 0.001 compared to Ad5). β-Gal
th 5000 vp/cell in the presence or absence of CD46 function-blocking
ype control, ** = p < 0.01 relative to isotype control).
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and HSVEC (Figure 2B).
To confirm that Ad5T*F35++ utilises CD46 as a recep-
tor, virus transduction was measured in the presence of
the CD46 specific antibody MEM258. The transduction
of both HSVSMC (Figure 2C) and HSVEC (Figure 2D)Figure 3 Effect of TIMP-3 over-expression in HSVSMC. HSVSMC were
Representative images of immunocytochemistry performed using rabbit
(in Ad5T*F35++ TIMP-3 infected cells). Scale bar = 10 μm B. Western blo
confirmed by β-actin detection. Ad5T*F35++ LacZ infections were perfo
TIMP-3. C. MTS assay performed 48 hours post infection. *p < 0.05 vs eq
post infection. The scratch width was measured at 0, 12 and 19 hours a
LacZ and ###p < 0.001 vs uninfected.was significantly reduced by the presence of MEM258,
confirming that the virus interaction with CD46 is a crit-
ical step in the transduction pathway using this modified
virus.
Therefore Ad5T*F35++ was found to bind to and trans-
duce HSVEC and HSVSMC more efficiently than Ad5,infected with 5 pfu/cell TIMP-3 expressing viruses. A.
anti-human TIMP-3 antibody (red) or the appropriate IgG control
t to detect TIMP-3 expression, with equivalent protein loading
rmed with both an equivalent pfu/cell and vp/cell as Ad5T*F35++
uivalent LacZ virus. D. Scratch assays were performed 48 hours
nd the percentage scratch closure was calculated. ***p < 0.001 vs
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Ad5T*F35++ expression of TIMP-3 inhibits SMC migration
and proliferation
To demonstrate the potential therapeutic use of
Ad5T*F35++, we produced a vector with this modified
configuration and an expression cassette encoding tissue
inhibitor of matrix metalloproteinase 3 (TIMP-3).
TIMP-3 is a promising candidate gene for gene therapy
to prevent vein graft failure as it has been shown to in-
hibit matrix metalloproteinase activity and it promotes
vascular SMC apoptosis [1,33,34]. It has previously been
demonstrated that adenoviral mediated over-expression
of TIMP-3 in porcine vein grafts significantly reduces
neointima formation in both a short term model [33]
and up to 3 months post engraftment [1].Figure 4 Effect of human sera on virus transduction. A. A549 cells wer
normalised to total protein levels. B-C. A549 cells were infected with 10,00
β-Gal activity was measured 48 hours post infection and normalised to tot
compared to no serum control. The red line indicates 90% inhibition of virIn order to investigate the potential benefit of the en-
hanced efficiency of the Ad5T*F35++ vector, experiments
using the TIMP-3 expressing vectors were performed using
a low dose of virus (5 pfu/cell). TIMP-3 over-expression
in transduced HSVSMC was confirmed by immunocyto-
chemistry (Figure 3A) and western blots (Figure 3B). This
demonstrated that Ad5T*F35++ TIMP-3 transduced cells
with high efficiency and mediated high levels of TIMP-3
expression, whereas both control vectors, Ad5 TIMP-3
and Ad5T* TIMP-3, led to the production of low levels of
ectopic TIMP-3.
To determine if the level of TIMP-3 expression achieved
was sufficient to have a functional effect, metabolic assays
were performed on transduced cells. In cells transduced
with Ad5T*F35++ TIMP-3, cell metabolism was signifi-
cantly reduced compared to Ad5T*F35++ LacZ (Figure 3C).
Infection of the Ad5 and Ad5T* vectors caused noe infected with a range of vp/cell as indicated. β-Gal activity was
0 vp/cell B. Ad5, C. Ad5T*F35++ in the presence of 2.5% human sera.
al protein levels. Graphs show the relative change in transduction
us transduction compared to no serum control sample.
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As TIMP-3 has also previously been shown to reduce
SMC migration, wound healing assays were performed in
transduced cells. Only Ad5T*F35++ TIMP-3 was found to
significantly reduce migration compared to the equivalent
LacZ control virus (Figure 3D). This suggests that due to
the more efficient vascular transduction of Ad5T*F35++,
compared to Ad5, a lower dose of vector may potentially
be required to mediate a therapeutic effect, although this
remains to be fully tested.
Earlier studies in this field suggested that the use of Ad
vectors to deliver genes to the vasculature can cause an in-
crease in neointima formation, probably due to a detrimen-
tal inflammatory response to the vector [35]. Although this
has not been seen in subsequent pig models [1], the in-
flammatory response to any vector needs to be carefully
investigated when considering clinical use. The increased
transduction efficiency of the Ad5T*F35++ may enable the
use of a lower dose to achieve a therapeutic effect and
therefore may be less likely to provoke an inflammatory re-
sponse. Also, a recent study has indicated that the innate
immune response to Ad is at least in part initiated by bind-
ing to FX [36], therefore ablating FX binding may also re-
duce the innate immune response that acts against the
vector.
Serum neutralisation of virus transduction
Another important consideration when developing a vector
for clinical applications is the effect of pre-existing neu-
tralising antibodies. Previous studies have provided evi-
dence of neutralising antibodies against both Ad5 hexon
[18] and fiber proteins [21] which significantly reduce virus
transduction [37]. Incorporation of hexon mutations [20]
or fiber pseudotyping [21] has been demonstrated to reduce
the neutralisation of Ad5 based vectors. In addition to im-
proving vascular transduction through altering receptor
usage, the Ad5T*35++ capsid modifications may also affect
the ability of pre-existing antibodies in human serum to
neutralise the virus. To determine if this is the case, trans-
duction assays were performed in the presence of a panel
of 102 human serum samples. The assay was performed in
A549 cells as transduction of the viruses was found to be
comparable in this cell type (Figure 4A). Thirty-three per-
cent of serum samples were found to reduce Ad5 transduc-
tion by at least 90%, (Figure 4B) where as Ad5T*F35++
transduction (Figure 4C) was neutralised by 18% of serum
samples. Therefore, we have shown that through modifying
the virus hexon and fiber protein we have engineered a vec-
tor which is less likely to be neutralised by a patient’s pre-
existing antibodies.
Conclusions
We have demonstrated that by combining mutations of
the Ad5 hexon and pseudotyping with the Ad35++ fiberwe have developed a vector which has many attributes
that suggest it could be a promising vector for efficient
gene delivery to the vasculature for the treatment of car-
diovascular diseases such as vein graft failure and in-stent
restenois. Further testing of this vector using in vivomodels
is required but, due to differences in CD46 expression pat-
terns in rodents [38] and non-human primates [39] and the
low level of homology between porcine and human CD46
[16], there are no appropriate animal models to further test
the efficacy of this vector. However, the efficacy of the virus
can be further tested using an established ex vivo model of
neointima formation in cultured human veins [40].
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